Feed NBIX
NB

Neurocrine Biosciences

NBIX · NASDAQ

$146.23 -4.11% (-$6.26)
1M -4.38%
Market Cap $15.3B
P/E Ratio 21.64x
Div. Yield -
ROE 21.13%

Bulios Fair Price

$141.55

3.2% downside

Current Price

$146.23

Undervalued Fair Value Overvalued

According to Bulios Fair Price, NBIX is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
5/9
Valuation
58 /100
Fair
P/FCF 17.54x
P/E 21.64x
P/B 4.13x
Growth
100 /100
Growing
FCF growth 32.36%
EPS growth 44.12%
Book val. growth 23.96%
Profitability
98 /100
Strong
Op. margin 23.38%
Gross margin 97.97%
FCF margin 25.80%
Quality
80 /100
Excellent
ROA 13.16%
ROIC 13.20%
Asset turnover 0.63x
Debt
99 /100
Low
Int. coverage 300.28x
Debt/Equity 0.11x
Net debt/EBITDA 0.08x
Stability
86 /100
Stable
EPS volatility 12.76%
Beta 0.38x
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NBIX
Online

About the company

Neurocrine Biosciences, Inc. is an American biotechnology company headquartered in San Francisco, California. The company focuses on the development of drugs for the treatment of neurological and endocrine disorders. Their main products include medications for the treatment of sleep disorders, movement disorders, and endocrine disorders such as diabetes. Neurocrine Biosciences specializes in research and development of new drug formulations targeting specific biological targets related to neurological and endocrine diseases. The company is known for its innovative drugs and technologies that help patients with these serious conditions. Shares of Neurocrine Biosciences, Inc. are publicly traded on the NASDAQ stock exchange.

Sector

Healthcare

Industry

Biotechnology

CEO

Kyle W. Gano

Employees

2,500

Headquarters

San Diego

Upcoming events

27 OCT

Earnings

Upcoming earnings report

38d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.